{ "abstract": "Background: Advances in tyrosine kinase inhibitor (TKI) therapy have substantially improved survival outcomes for patients with chronic myeloid leukemia (CML). As patients increasingly achieve long-term disease control, health-related quality of life (HRQoL) has become an important treatment outcome. Aim: To characterize HRQoL and health utility scores among Brazilian patients with chronic-phase CML receiving TKI and to explore associations between treatment line and comorbidity burden on patient-reported outcomes. Materials and methods: This prospective, cross-sectional, non-interventional study enrolled Brazilian adults (≥ 18 years) with confirmed chronic-phase CML receiving an approved TKI for at least 1 month. Participants were recruited through the Brazilian Blood Cancer Association (ABRALE). Following ethics committee approval, eligible participants provided electronic informed consent and completed structured self-administered digital questionnaires through an electronic platform. HRQoL was assessed using the EuroQol 5-Dimension 3-Level questionnaire (EQ-5D-3L) and the EQ Visual Analogue Scale (EQ-VAS). EQ-5D-3L utility scores were derived using the Brazilian time trade-off (TTO) value set developed by Santos et al. Patients unwilling or unable to provide informed consent or currently participating in an interventional clinical trial were excluded. Results: Of 216 respondents, 137 were eligible for inclusion after excluding patients with non–chronic-phase CML (n = 4), participation in or uncertainty regarding participation in an interventional clinical trial (n = 22), no current TKI treatment (n = 46), or age < 18 lt; 18 years (n = 7). Of these, 99 completed the EQ-5D-3L and were included in the HRQoL analysis. Participants were predominantly female (61.6%), aged 40–59 years (46.5%), White (65.7%), residing in Southeastern Brazil (52.5%), and had a university degree (41.4%); 52.5% received care through private health insurance. Regarding treatment history, 40 (40.4%) patients were receiving first-line (1L) TKI therapy, 35 (35.4%) second-line (2L) therapy, and 24 (24.2%) third-line or later (≥ 3L) therapy. Overall, 45.5% of patients reported no comorbidities, 32.3% reported one comorbidity, and 22.2% reported two or more comorbidities. The mean EQ-5D-3L utility score was 0.748 (95% CI, 0.716–0.780), and the mean EQ-VAS score was 73.5 (95% CI, 69.9–77.0). Mean EQ-5D-3L utility scores were 0.766 (95% CI: 0.720–0.812), 0.762 (95% CI: 0.715–0.810), and 0.696 (95% CI: 0.615–0.777) among patients receiving 1L, 2L, and ≥ 3L therapy, respectively. HRQoL decreased progressively with increasing comorbidity burden, with mean EQ-5D-3L utility scores of 0.826 (95% CI, 0.784–0.869) among patients without comorbidities, 0.706 (95% CI, 0.659–0.753) among those with one comorbidity, and 0.648 (95% CI, 0.582–0.714) among those with ≥ 2 comorbidities (Kruskal–Wallis p < 0.001). Conclusion: This study provides one of the first real-world assessments of HRQoL and health utility among Brazilian patients with chronic-phase CML receiving TKI therapy. Overall, HRQoL was favorable; however, lower utility scores were observed among patients receiving third-line or later treatment and among those with a higher comorbidity burden. The progressive decline in HRQoL with increasing comorbidity burden highlights the impact of comorbid conditions on patient well-being beyond leukemia control alone.", "abstract_shown": true, "affiliations": [ "Novartis Biociências S.A., São Paulo, SP, Brazil", "Associação Brasileira de Câncer do Sangue (Abrale), São Paulo, SP, Brazil" ], "article_type": null, "arxiv": null, "author_total": 12, "authors": [ { "affs": [ 0 ], "name": "Diego KASHIURA" }, { "affs": [ 0 ], "name": "Diogo NOIN DE OLIVEIRA" }, { "affs": [ 0 ], "name": "Ana Beatriz MACHADO DE ALMEIDA" }, { "affs": [ 0 ], "name": "Alessandro BIGONI" }, { "affs": [ 0 ], "name": "Priscila RAUPP DA ROSA" }, { "affs": [ 0 ], "name": "Leonardo Hiago GATTAS" }, { "affs": [ 0 ], "name": "Michelly Yumi TUBONE DONI" }, { "affs": [ 0 ], "name": "Jamile COUTRIM DALRI" }, { "affs": [ 1 ], "name": "Nina MELO" }, { "affs": [ 1 ], "name": "Janaina ROSENBURG GIOSEFF" }, { "affs": [ 1 ], "name": "Catherine MOURA DA FONSECA PINTO" }, { "affs": [ 0 ], "name": "Lucas Kaoru KOBO FERREIRA" } ], "bibtex": "https://research.draconitic.com/paper/60rxf6wby1y7n.bib", "cited_by": 0, "doi": "10.1016/j.htct.2026.107507", "fulltext_url": "http://www.sciencedirect.com/science/article/pii/S253113792601254X", "id": "60rxf6wby1y7n", "issns": [ "2531-1379", "2531-1387" ], "landing_url": "https://doi.org/10.1016/j.htct.2026.107507", "language": "en", "licence": "CC-BY", "licence_label": "CC BY", "licence_source": "journal", "licence_url": "https://creativecommons.org/licenses/by/4.0/", "metadata_licence": null, "native_subjects": [ [ "lcc", "RC633-647.5" ], [ "openalex", "2002|Health Systems, Economic Evaluations, Quality of Life" ] ], "openalex": "W7223089891", "pdf_url": "https://www.sciencedirect.com/science/article/pii/S253113792601254X/pdf", "pmcid": null, "pmid": null, "published": "2026-10-23", "publisher": "Elsevier", "ris": "https://research.draconitic.com/paper/60rxf6wby1y7n.ris", "sources": [ { "first_seen": "2026-10-30T13:43:18Z", "native_id": "3a8b95a0e8954e698bd3471011257cb3", "source": "doaj", "url": "https://doi.org/10.1016/j.htct.2026.107507" } ], "subjects": [ { "field": "medicine", "origin": "lcc:RC633-647.5", "subfield": "endocrinology-metabolism" } ], "title": "HEALTH-RELATED QUALITY OF LIFE AND HEALTH UTILITY AMONG BRAZILIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM BRAZIL", "title_text": "HEALTH-RELATED QUALITY OF LIFE AND HEALTH UTILITY AMONG BRAZILIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM BRAZIL", "type": "peer-reviewed", "updated_at": "2026-10-30T13:43:18Z", "url": "https://research.draconitic.com/paper/60rxf6wby1y7n", "venue": "Hematology, Transfusion and Cell Therapy", "versions": [] }